Virtus Biotech Clinical Trials ETF BBC
43.62 USD +0.81 (+1.89%)
Nov 4, 2026, 9:55 AM EST
43.62 Day range 43.85
28.73 52-week range 56.18
- YTD
- +13.12%
- 1 year
- +43.53%
- Market cap
- 34.25M
- YTD return
- +13.12%
- 1-year return
- +43.53%
- Volume
- 1.03K
- Avg volume
- 24.97K
- Open
- 43.85
- Previous close
- 42.81
- Day's range
- 43.62 – 43.85
- 52-week range
- 28.73 – 56.18
1Y +13.89 (+46.38%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 27.91
- 200-day average
- 27.48
About Virtus Biotech Clinical Trials ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
News
Trasteel Holding S.A. Completes Acquisition of the Remaining 40% Interest in BBC Alloys S.r.l. 
Venture Into High-Volatility Corners of the Market With These 3 ETFs 
Trump wins last-minute reprieve temporarily blocking BBC access to his business records 
Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Sees Large Growth in Short Interest 
Biotech ETF (BBC) Touches Fresh 52-Week High 
Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Sees Significant Increase in Short Interest 
What's Going On With Alumis Stock Thursday? 
Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026? 
Biotech ETF (BBC) Hits New 52-Week High 
Healthcare ETFs Trounce Tech, Grab Billions As Big Money Flees Bubble Fears
Your note
Sign in to keep a note on BBC — it syncs with the Stock Master app.